<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857685</url>
  </required_header>
  <id_info>
    <org_study_id>Proliferation</org_study_id>
    <nct_id>NCT03857685</nct_id>
  </id_info>
  <brief_title>LEC Proliferation in Vivo and In-vitro</brief_title>
  <official_title>Bilateral and Age-dependent Differences in Posterior Capsule Opacification in Vivo Compared to an In-vitro Mode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prim. Prof. Dr. Oliver Findl, MBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the proliferative capacity of individual lens epithelium capsule specimens in&#xD;
      vitro and correlate it to the risk of developing PCO&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cataract, the clouding of the eye's lens, is still the leading cause of blindness worldwide.&#xD;
      Until now surgery is the only therapy available for the disease. Cataract surgery is nowadays&#xD;
      considered a safe and efficient therapy. However, one of the most frequent complications of&#xD;
      cataract surgery is posterior capsule opacification (PCO), which results in diminished&#xD;
      postoperative visual acuity. PCO occurs due to a robust wound-healing response, where&#xD;
      remaining lens epithelial cells in the capsular bag start to migrate and proliferate.&#xD;
&#xD;
      The lens capsule is divided into an anterior, an equatorial, and a posterior region. The&#xD;
      anterior and the equatorial region consist of a single layer of cuboidal epithelial cells,&#xD;
      whilst the posterior region is formed of fibers. In the adult lens proliferation occurs&#xD;
      almost exclusively in the equatorial region and although the central part of the lens&#xD;
      epithelium exhibits very low mitotic activity, it was shown in experiments that cell in this&#xD;
      area are also stem cells. There are three possible reasons for the generation of PCO:&#xD;
      intraoperative factors (dependening on the amount of remaining cells in the capsular bag),&#xD;
      intraocular lens factors, and interpersonal factor (patient-specific factors).&#xD;
&#xD;
      Aim of this study is the generation of an in-vitro model of posterior capsule opacification.&#xD;
      Therefore, the investigators will analyse the proliferative capacity of lens epithelial cells&#xD;
      on the lens capsule, which is removed during cataract surgery, in a cell culture model. The&#xD;
      investigators then compare the proliferative capacity between young and old patients, between&#xD;
      both eyes of the same patient, and in different forms of cataract.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of proliferation of lens epithelial cells (LECs) in-vitro compared to in vivo in the same patient</measure>
    <time_frame>24 months</time_frame>
    <description>Proliferation of LECs in-vitro will be measured as area/mm2 and correlated with ratings of posterior capsular opacification in vivo using a scale from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of proliferation of LECs in-vitro in young and older patients</measure>
    <time_frame>24 months</time_frame>
    <description>Proliferation of LECs in-vitro will be measured as area/mm2 and compared between older and younger individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of proliferation of LECs in-vitro between different forms of cataract</measure>
    <time_frame>24 months</time_frame>
    <description>Proliferation of LECs in-vitro will be measured as area/mm2 and compared between the different forms of cataract (cortical, nuclear, posterior subcapsular)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Posterior Capsule Opacification</condition>
  <arm_group>
    <arm_group_label>Proliferation in an in-vitro model</arm_group_label>
    <description>An in-vitro model is used to study lens epithelial cell proliferation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In-vitro model</intervention_name>
    <description>In-vitro model of posterior capsule opacification by culturing the lens capsule</description>
    <arm_group_label>Proliferation in an in-vitro model</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing cataract surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age-related cataract.&#xD;
&#xD;
          -  Patients in the age group of 21 years and older.&#xD;
&#xD;
          -  Patients with uncomplicated cataract.&#xD;
&#xD;
          -  Patients without any relevant systemic or ocular morbidity.&#xD;
&#xD;
          -  Patients with well dilating pupils.&#xD;
&#xD;
          -  Written informed consent prior to any study specific action.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with complicated cataract.&#xD;
&#xD;
          -  Patients with big differences in LOCS scale between the two eyes.&#xD;
&#xD;
          -  Patients having corneal pathology.&#xD;
&#xD;
          -  Patients with any form of ocular inflammation.&#xD;
&#xD;
          -  Patients with glaucoma, retinal pathologies.&#xD;
&#xD;
          -  Patients with traumatic cataracts, subluxated and dislocated lens, prior h/o ocular&#xD;
             surgery, pseudoexfoliation.&#xD;
&#xD;
          -  Any intraoperative complications like posterior capsule rupture.&#xD;
&#xD;
          -  In case of pregnancy (pregnancy test will be taken preoperatively in women of&#xD;
             reproductive age).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreea Fisus, MD</last_name>
    <phone>01 91021-57564</phone>
    <email>office@viros.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Ruiß, MSc.</last_name>
    <phone>01 91021-57564</phone>
    <email>office@viros.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery (VIROS)</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreea Fisus, MD</last_name>
      <phone>01 91021-57564</phone>
      <email>office@viros.at</email>
    </contact>
    <contact_backup>
      <last_name>Manuel Ruiß, MSc.</last_name>
      <phone>01 91021-57564</phone>
      <email>office@viros.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lens capsule</keyword>
  <keyword>Proliferation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

